JP2008520187A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008520187A5 JP2008520187A5 JP2007537962A JP2007537962A JP2008520187A5 JP 2008520187 A5 JP2008520187 A5 JP 2008520187A5 JP 2007537962 A JP2007537962 A JP 2007537962A JP 2007537962 A JP2007537962 A JP 2007537962A JP 2008520187 A5 JP2008520187 A5 JP 2008520187A5
- Authority
- JP
- Japan
- Prior art keywords
- flavivirus
- chimeric
- mutation
- chimeric flavivirus
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000710831 Flavivirus Species 0.000 claims 69
- 230000035772 mutation Effects 0.000 claims 32
- 235000001014 amino acid Nutrition 0.000 claims 17
- 108010052285 Membrane Proteins Proteins 0.000 claims 16
- 102000018697 Membrane Proteins Human genes 0.000 claims 16
- 150000001413 amino acids Chemical class 0.000 claims 14
- 101710132601 Capsid protein Proteins 0.000 claims 13
- 101710094648 Coat protein Proteins 0.000 claims 13
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims 13
- 101710125418 Major capsid protein Proteins 0.000 claims 13
- 101710141454 Nucleoprotein Proteins 0.000 claims 13
- 101710083689 Probable capsid protein Proteins 0.000 claims 13
- 241000710886 West Nile virus Species 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 239000012528 membrane Substances 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 7
- 241000710842 Japanese encephalitis virus Species 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- 208000001490 Dengue Diseases 0.000 claims 5
- 206010012310 Dengue fever Diseases 0.000 claims 5
- 241000700605 Viruses Species 0.000 claims 5
- 208000025729 dengue disease Diseases 0.000 claims 5
- 241000710772 Yellow fever virus Species 0.000 claims 3
- 125000003275 alpha amino acid group Chemical class 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 229940051021 yellow-fever virus Drugs 0.000 claims 3
- 241000725619 Dengue virus Species 0.000 claims 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
- 101710172711 Structural protein Proteins 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- 108090000565 Capsid Proteins Proteins 0.000 claims 1
- 102100023321 Ceruloplasmin Human genes 0.000 claims 1
- 101710091045 Envelope protein Proteins 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 101710188315 Protein X Proteins 0.000 claims 1
- 241000710888 St. Louis encephalitis virus Species 0.000 claims 1
- 102100021696 Syncytin-1 Human genes 0.000 claims 1
- 108091036066 Three prime untranslated region Proteins 0.000 claims 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 claims 1
- 206010058874 Viraemia Diseases 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 125000000404 glutamine group Chemical class N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 125000001909 leucine group Chemical class [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000149 penetrating effect Effects 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 239000012679 serum free medium Substances 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
- 210000003501 vero cell Anatomy 0.000 claims 1
- 230000029812 viral genome replication Effects 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62046604P | 2004-10-20 | 2004-10-20 | |
| US60/620,466 | 2004-10-20 | ||
| US62094804P | 2004-10-21 | 2004-10-21 | |
| US60/620,948 | 2004-10-21 | ||
| US67441505P | 2005-04-24 | 2005-04-24 | |
| US60/674,415 | 2005-04-24 | ||
| US67454605P | 2005-04-25 | 2005-04-25 | |
| US60/674,546 | 2005-04-25 | ||
| US71892305P | 2005-09-19 | 2005-09-19 | |
| US60/718,923 | 2005-09-19 | ||
| PCT/US2005/037369 WO2006044857A2 (en) | 2004-10-20 | 2005-10-19 | Vaccines against japanese encephalitis virus and west nile virus |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008520187A JP2008520187A (ja) | 2008-06-19 |
| JP2008520187A5 true JP2008520187A5 (cg-RX-API-DMAC7.html) | 2011-02-03 |
| JP4993301B2 JP4993301B2 (ja) | 2012-08-08 |
Family
ID=36203650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007537962A Expired - Lifetime JP4993301B2 (ja) | 2004-10-20 | 2005-10-19 | 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8029802B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1809325B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4993301B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101501162B1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005295438B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2584228C (cg-RX-API-DMAC7.html) |
| EA (1) | EA015907B1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL182453A0 (cg-RX-API-DMAC7.html) |
| MY (1) | MY148075A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20071924L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ584079A (cg-RX-API-DMAC7.html) |
| SG (1) | SG156666A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006044857A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL371187A1 (en) | 2001-06-01 | 2005-06-13 | Acambis, Inc. | Chimeric flavivirus vectors |
| AU2003267937C1 (en) | 2002-01-15 | 2019-08-08 | Sanofi Pasteur Biologics, Llc | Flavivirus vaccines |
| JP4683926B2 (ja) | 2002-11-15 | 2011-05-18 | サノフィ パスツール バイオロジクス カンパニー | ウエストナイルウイルス・ワクチン |
| US8029802B2 (en) | 2004-10-20 | 2011-10-04 | Sanofi Pasteur Biologics Co. | Vaccines against Japanese encephalitis virus and West Nile virus |
| AU2013204985B2 (en) * | 2005-04-24 | 2016-01-28 | Sanofi Pasteur Biologics, Llc | Recombinant flavivirus vaccines |
| BRPI0609949A2 (pt) | 2005-04-24 | 2010-05-11 | Acambis Inc | flavivìrus recombinante, seu uso na preparação de vacina, composição farmacêutica compreendendo o mesmo, molécula de ácido nucléico e método para atenuar candidato a vacina de flavivìrus |
| AU2007303608B2 (en) | 2006-09-29 | 2013-05-02 | Takeda Vaccines, Inc. | Norovirus vaccine formulations |
| EP2086581B1 (en) | 2006-11-07 | 2014-08-13 | Sanofi Pasteur Biologics, LLC | Stabilization of vaccines by lyophilization |
| WO2008115314A2 (en) * | 2007-01-31 | 2008-09-25 | Sanofi Pasteur Biologics Co. | Flavivirus vaccine vector against influenza virus |
| US10130696B2 (en) | 2007-09-18 | 2018-11-20 | Takeda Vaccines, Inc. | Method of conferring a protective immune response to norovirus |
| US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
| AU2009241354B2 (en) * | 2008-04-30 | 2014-06-12 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Chimeric West Nile/Dengue viruses |
| SG2013057732A (en) | 2008-08-08 | 2015-02-27 | Ligocyte Pharmaceuticals Inc | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
| CA3001374A1 (en) * | 2008-11-17 | 2010-05-20 | Vgx Pharmaceuticals, Llc | Antigens that elicit immune response against flavivirus and methods of using same |
| US8968996B2 (en) | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
| MX343172B (es) | 2009-06-01 | 2016-10-26 | Takeda Vaccines Inc | Composiciones y metodos para administracion de vacunas contra virus del dengue. |
| CA3150404A1 (en) | 2009-07-31 | 2011-02-03 | Pnuvax Inc. | High yield yellow fever virus strain with increased propagation in cells |
| US10081795B2 (en) * | 2010-03-24 | 2018-09-25 | Research Development Foundation | Flavivirus host range mutations and uses thereof |
| CN101926989A (zh) * | 2010-06-29 | 2010-12-29 | 西北农林科技大学 | 表达jev免疫原基因的重组减毒鼠伤寒沙门氏菌载体疫苗及其制备方法 |
| WO2012003320A2 (en) * | 2010-07-01 | 2012-01-05 | Research Development Foundation | Flavivirus host-range mutations and uses thereof |
| EA202090699A3 (ru) | 2011-07-11 | 2020-11-30 | Такеда Вэксинс, Инк. | Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения |
| US9267114B2 (en) * | 2012-11-07 | 2016-02-23 | Southern Research Institute | Flavivirus envelope protein mutations affecting virion disassembly |
| US9878031B2 (en) | 2012-12-14 | 2018-01-30 | Takeda Vaccines, Inc. | Compositions, methods of administration and uses for trivalent dengue virus formulations |
| JP2016523251A (ja) | 2013-06-21 | 2016-08-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | デングウイルスワクチン組成物およびその使用方法 |
| AU2014302282B2 (en) | 2013-06-26 | 2018-09-13 | The University Of North Carolina At Chapel Hill | Methods and compositions for dengue virus vaccines |
| WO2016079560A1 (en) | 2014-11-21 | 2016-05-26 | Institut Pasteur | A live and attenuated japanese encephalitis virus comprising a mutated m protein |
| AU2015369875A1 (en) | 2014-12-22 | 2017-06-15 | Merck Sharp & Dohme Corp. | Dengue virus vaccine compositions and methods of use thereof |
| EA035921B1 (ru) * | 2015-07-16 | 2020-08-31 | Бхарат Байотек Интернэшнл Лимитед | Вакцинные композиции для профилактики арбовирусных инфекций |
| WO2020194063A1 (en) * | 2019-03-28 | 2020-10-01 | Institut Pasteur | A live and attenuated flavivirus comprising a mutated m protein |
| WO2024254552A1 (en) * | 2023-06-08 | 2024-12-12 | Modernatx, Inc. | Stabilized flavivirus vaccines |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5173418A (en) | 1985-05-10 | 1992-12-22 | Benzon Pharma, A/S | Production in Escherichia coli of extracellular Serratia spp. hydrolases |
| US6676936B1 (en) | 1988-07-14 | 2004-01-13 | The United States Of America As Represented By The Department Of Health And Human Services. | Chimeric and/or growth-restricted flaviviruses |
| US6184024B1 (en) | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
| US6962708B1 (en) | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
| NZ337522A (en) * | 1997-02-28 | 2001-02-23 | St | Chimeric flavivirus incorporating yellow fever virus modified such that a prM-E protein of a second flavivirus is expressed, and vaccines for flavivruses |
| US6589533B1 (en) | 1997-09-18 | 2003-07-08 | Research Development Foundation | Genetically-engineered alphaviruses, flaviviruses, and bunyaviruses with modified envelope transmembrane glycoproteins and altered host-range phenotype |
| AU9794198A (en) | 1997-10-08 | 1999-04-27 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Chimeric vaccine against tick-borne encephalitis virus |
| US7227011B2 (en) * | 1998-06-04 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
| WO2001039802A1 (en) | 1999-12-01 | 2001-06-07 | Oravax, Inc. | Chimeric flavivirus vaccines |
| WO2002081753A1 (en) | 2001-04-04 | 2002-10-17 | Advanced Research & Technology Institute | Method for identifying and characterizing individual dna molecules |
| WO2003060088A2 (en) | 2002-01-15 | 2003-07-24 | Acambis, Inc. | Viral vaccine production method |
| US20050002968A1 (en) | 2002-01-15 | 2005-01-06 | Monath Thomas P. | Flavivirus vaccines |
| AU2003267937C1 (en) * | 2002-01-15 | 2019-08-08 | Sanofi Pasteur Biologics, Llc | Flavivirus vaccines |
| JP4683926B2 (ja) * | 2002-11-15 | 2011-05-18 | サノフィ パスツール バイオロジクス カンパニー | ウエストナイルウイルス・ワクチン |
| US7189403B2 (en) * | 2003-06-30 | 2007-03-13 | Institut Pasteur | Attenuated flavivirus strains containing a mutated M-ectodomain and their applications |
| US8029802B2 (en) | 2004-10-20 | 2011-10-04 | Sanofi Pasteur Biologics Co. | Vaccines against Japanese encephalitis virus and West Nile virus |
| BRPI0609949A2 (pt) | 2005-04-24 | 2010-05-11 | Acambis Inc | flavivìrus recombinante, seu uso na preparação de vacina, composição farmacêutica compreendendo o mesmo, molécula de ácido nucléico e método para atenuar candidato a vacina de flavivìrus |
-
2005
- 2005-10-19 US US11/577,569 patent/US8029802B2/en active Active
- 2005-10-19 SG SG200906992-3A patent/SG156666A1/en unknown
- 2005-10-19 JP JP2007537962A patent/JP4993301B2/ja not_active Expired - Lifetime
- 2005-10-19 EA EA200700904A patent/EA015907B1/ru not_active IP Right Cessation
- 2005-10-19 EP EP05811861.3A patent/EP1809325B1/en not_active Expired - Lifetime
- 2005-10-19 WO PCT/US2005/037369 patent/WO2006044857A2/en not_active Ceased
- 2005-10-19 NZ NZ584079A patent/NZ584079A/en not_active IP Right Cessation
- 2005-10-19 CA CA2584228A patent/CA2584228C/en not_active Expired - Lifetime
- 2005-10-19 KR KR1020077011389A patent/KR101501162B1/ko not_active Expired - Lifetime
- 2005-10-19 AU AU2005295438A patent/AU2005295438B2/en not_active Expired
- 2005-10-20 MY MYPI20054938A patent/MY148075A/en unknown
-
2007
- 2007-04-11 IL IL182453A patent/IL182453A0/en unknown
- 2007-04-16 NO NO20071924A patent/NO20071924L/no not_active Application Discontinuation
-
2011
- 2011-10-03 US US13/251,424 patent/US8691550B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008520187A5 (cg-RX-API-DMAC7.html) | ||
| CA2584228A1 (en) | Vaccines against japanese encephalitis virus and west nile virus | |
| Zeng et al. | Identification of specific nucleotide sequences within the conserved 3′-SL in the dengue type 2 virus genome required for replication | |
| McMinn | The molecular basis of virulence of the encephalitogenic flaviviruses. | |
| Gualano et al. | Identification of a major determinant of mouse neurovirulence of dengue virus type 2 using stably cloned genomic-length cDNA | |
| Xie et al. | Targeting dengue virus NS4B protein for drug discovery | |
| Fu et al. | Full-length cDNA sequence of dengue type 1 virus (Singapore strain S275/90) | |
| Tilgner et al. | The flavivirus-conserved penta-nucleotide in the 3′ stem-loop of the West Nile virus genome requires a specific sequence and structure for RNA synthesis, but not for viral translation | |
| Pang et al. | Development of Dengue virus type 2 replicons capable of prolonged expression in host cells | |
| Qi et al. | Biological characteristics of dengue virus and potential targets for drug design | |
| US8871222B2 (en) | Recombinant Flavivirus vaccines | |
| Rossi et al. | Genetic and phenotypic characterization of sylvatic dengue virus type 4 strains | |
| Hayasaka et al. | Amino acid changes responsible for attenuation of virus neurovirulence in an infectious cDNA clone of the Oshima strain of tick-borne encephalitis virus | |
| Schlick et al. | Helices α2 and α3 of West Nile virus capsid protein are dispensable for assembly of infectious virions | |
| Maloney et al. | Identification of the flavivirus conserved residues in the envelope protein hinge region for the rational design of a candidate West Nile live-attenuated vaccine | |
| Yoshii et al. | Construction of an infectious cDNA clone for Omsk hemorrhagic fever virus, and characterization of mutations in NS2A and NS5 | |
| Liu et al. | Homologous RNA secondary structure duplications in 3′ untranslated region influence subgenomic RNA production and replication of dengue virus | |
| Tajima et al. | Restoration of replication-defective dengue type 1 virus bearing mutations in the N-terminal cytoplasmic portion of NS4A by additional mutations in NS4B | |
| Frimayanti et al. | Fragment-based molecular design of new competitive dengue Den2 Ns2b/Ns3 inhibitors from the components of fingerroot (Boesenbergia rotunda) | |
| Růžek et al. | Virology. Chapter 2a | |
| TH64126B (th) | วัคซีนต้านไวรัสไข้สมองอักเสบและเวสต์ไนล์ไวรัส | |
| TH77925A (th) | วัคซีนต้านไวรัสไข้สมองอักเสบและเวสต์ไนล์ไวรัส | |
| Růžek et al. | Chapter 4. TBE virology | |
| Ramos-Lorente et al. | The 3żUTR of the West Nile Virus genomic RNA is a potential antiviral target site | |
| Le | Comparison of sequences and structures between NS3-NS2B of various Flaviviruses |